Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Crystallization products of risedronate with carbohydrates and their substituted derivatives

J. Kos, M. Pentakova, Z. Oktabec, L. Krejcik, Z. Mandelova, P. Harokova, J. Hruskova, T. Pekarek, O. Dammer, M. Tkadlecova, J. Havlicek, J. Vinsova, V. Kral, J. Dohnal, J. Jampílek,

. 2011 ; 16 (5) : 3740-60. [pub] 20110504

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12027564

The gastrointestinal absorption of bisphosphonates is in general only about 1%. To address this problem mixtures of risedronate monosodium salt with twelve varied sugar alcohols, furanoses, pyranoses and eight gluco-, manno- and galactopyranoside derivatives as counterions were designed in an effort to prepare co-crystals/new entities with improved intestinal absorption. Crystalline forms were generated by means of kinetically and/or thermodynamically controlled crystallization processes. One hundred and fifty-two prepared samples were screened by means of FT-NIR and FT-Raman spectroscopy. No co-crystal was prepared, but noteworthy results were obtained. A new solid phase of risedronate monosodium salt generated in the presence of phenyl-β-d-galactopyranoside under thermodynamically controlled crystallization conditions was found and also characterized using solid state NMR spectroscopy, X-ray powder diffraction and differential scanning calorimetry. This new polymorph was named as form P. Interactions between risedronate monosodium salt and both carbohydrates were confirmed by means of molecular dynamics simulation. In the present study the relationships between the chemical structures of the studied compounds required for crystalline form change are discussed.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027564
003      
CZ-PrNML
005      
20230703090643.0
007      
ta
008      
120817s2011 sz f 000 0#eng||
009      
AR
024    7_
$a 10.3390/molecules16053740 $2 doi
035    __
$a (PubMed)21544038
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kos, Jiri $u Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho 1/3, 61242 Brno, Czech Republic.
245    10
$a Crystallization products of risedronate with carbohydrates and their substituted derivatives / $c J. Kos, M. Pentakova, Z. Oktabec, L. Krejcik, Z. Mandelova, P. Harokova, J. Hruskova, T. Pekarek, O. Dammer, M. Tkadlecova, J. Havlicek, J. Vinsova, V. Kral, J. Dohnal, J. Jampílek,
520    9_
$a The gastrointestinal absorption of bisphosphonates is in general only about 1%. To address this problem mixtures of risedronate monosodium salt with twelve varied sugar alcohols, furanoses, pyranoses and eight gluco-, manno- and galactopyranoside derivatives as counterions were designed in an effort to prepare co-crystals/new entities with improved intestinal absorption. Crystalline forms were generated by means of kinetically and/or thermodynamically controlled crystallization processes. One hundred and fifty-two prepared samples were screened by means of FT-NIR and FT-Raman spectroscopy. No co-crystal was prepared, but noteworthy results were obtained. A new solid phase of risedronate monosodium salt generated in the presence of phenyl-β-d-galactopyranoside under thermodynamically controlled crystallization conditions was found and also characterized using solid state NMR spectroscopy, X-ray powder diffraction and differential scanning calorimetry. This new polymorph was named as form P. Interactions between risedronate monosodium salt and both carbohydrates were confirmed by means of molecular dynamics simulation. In the present study the relationships between the chemical structures of the studied compounds required for crystalline form change are discussed.
650    _2
$a diferenciální skenovací kalorimetrie $7 D002152
650    _2
$a sacharidy $x chemie $7 D002241
650    _2
$a krystalizace $7 D003460
650    _2
$a kyselina etidronová $x analogy a deriváty $x chemie $7 D012968
650    _2
$a galaktosidy $x chemie $7 D005697
650    _2
$a magnetická rezonanční spektroskopie $7 D009682
650    _2
$a molekulární struktura $7 D015394
650    _2
$a spektroskopie infračervená s Fourierovou transformací $7 D017550
650    _2
$a Ramanova spektroskopie $7 D013059
650    _2
$a difrakce rentgenového záření $7 D014961
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pentakova, Monika
700    1_
$a Oktábec, Zbyněk $7 xx0230115
700    1_
$a Krejcik, Lukas
700    1_
$a Mandelova, Zuzana
700    1_
$a Harokova, Pavla
700    1_
$a Hruskova, Jana
700    1_
$a Pekarek, Tomas
700    1_
$a Dammer, Ondřej $7 xx0303489
700    1_
$a Tkadlecova, Marcela
700    1_
$a Havlicek, Jaroslav
700    1_
$a Vinsova, Jarmila
700    1_
$a Kral, Vladimir
700    1_
$a Dohnal, Jiri
700    1_
$a Jampílek, Josef
773    0_
$w MED00180394 $t Molecules $x 1420-3049 $g Roč. 16, č. 5 (2011), s. 3740-60
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21544038 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20230703090642 $b ABA008
999    __
$a ok $b bmc $g 949606 $s 784910
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 16 $c 5 $d 3740-60 $e 20110504 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
LZP    __
$a Pubmed-20120817/11/03

Find record

Citation metrics

Archiving options